Screener
Ligand Pharmaceuticals LGND PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's PP&E (net)?
- Ligand Pharmaceuticals (LGND) reported PP&E (net) of $3.4M in Q2 2026.
- How has Ligand Pharmaceuticals's PP&E (net) changed year-over-year?
- Ligand Pharmaceuticals's PP&E (net) decreased by 6.5% year-over-year, from $3.63M to $3.4M.
- What is the long-term trend for Ligand Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's PP&E (net) has grown at a -23.0% compound annual growth rate (CAGR), from $13.19M to $3.57M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Ligand Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude